Improving clinician-ordered genomic risk prediction for common diseases.
The risk of heart attack, diabetes, chronic kidney disease, and other common conditions can be assessed early in adulthood using polygenic risk scores, rare pathogenic variants, and family history — enabling targeted screening and treatment that reduce adverse events. ARC-OMIX turns that prediction into a clinical-grade workflow that preventive and primary-care teams can use.
Two decades of polygenic risk research, built for the clinic.
ARC-OMIX was founded by Dr. Iftikhar J. Kullo, Professor of Medicine and Associate Director of the Mellowes Center for Genomic Sciences and Precision Medicine at the Medical College of Wisconsin, and one of the world’s leading authorities on polygenic risk scores. His work spans more than two decades developing and validating polygenic risk scores for a range of traits and diseases. All sequencing is performed by our partner lab.
Mayo Clinic
Establishes one of the earliest preventive-genomics research programs.
MI-GENES trial
Returns polygenic risk results directly to primary-care patients; published in Circulation.
ClinGen FH VCEP
Co-chairs the ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel.
eMERGE & PRIMED
Principal investigator; the PRSMix ensemble methodology was developed and validated through the PRIMED Consortium.
ARC-OMIX, LLC
Incorporated under a Medical College of Wisconsin license, and built from the outset around a CLIA-certified, CAP-accredited partner laboratory.
Principles guiding our approach.
Risk identified early can be acted on early
The highest-value moment in preventive medicine is before symptoms appear. Genetic risk information at 35 or 45 is far more actionable than a diagnosis at 60.
Clinical tools must meet clinical evidence standards
Polygenic risk has been validated in population studies with millions of participants. Every ARC-OMIX report will show the evidence behind each score, including where validation is still in progress, and we do not present uncertainty as clarity.
Genetic risk tools must work across ancestries
Early polygenic tools were trained predominantly on European-ancestry populations, reducing their accuracy elsewhere. ARC-OMIX treats ancestry-calibrated training and validation as a non-negotiable design requirement, supporting broad applicability across ancestrally varied populations.
A test must fit the clinical workflow.
Many promising diagnostics failed to reach patients because they were too difficult to order, interpret, or act on. ARC-OMIX is designed to fit a 20-minute visit.
Built on established science and institutional partnerships.
Research consortia
Dr. Kullo serves as principal investigator on PRIMED and eMERGE — two of the largest multi-ancestry genomic research programs in the U.S. ARC-OMIX scores are calibrated against multi-ancestry reference populations exceeding 100,000 individuals.
Laboratory partner
Sequencing is performed by our partner lab, a CLIA-certified, CAP-accredited facility whose Blended Genome-Exome platform provides the sequencing infrastructure underlying every ARC-OMIX test.
Genetic counseling
ABGC-certified genetic counselors are available via telehealth for all patients and providers. Counseling is triggered automatically on monogenic-positive findings.
Have a question?
Email us at info@arc-omix.com, or fill out the form below.